Highlights of weekly biotech stock moves

Alimera Sciences Inc. (NASDAQ:ALIM) was off $0.15 to $6.31 last week after saying FDA accepted for review a resubmitted NDA for Iluvien fluocinolone acetonide intravitreal implant to treat diabetic macular edema (DME). The PDUFA date is Sept. 26. FDA issued a complete response letter in October.

Alimera has rights to Iluvien from pSivida Corp. (NASDAQ:PSDV; ASX:PVA), which was up A$0.02 to A$4.02 on ASX and up $0.02 to $3.45 on NASDAQ...